Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101

14 Jan 2025 07:00 CET

Issuer

BIOPHYTIS

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_1308763_PR_Biophytis_Partbership_China_VDEF_VENG.pdf

Source

Biophytis

Provider

Les Echos

Company Name

BIOPHYTIS

ISIN

FR001400OLP5

Symbol

ALBPS

Market

Euronext Growth

Home
Markets
- Amsterdam
  - Cash Products
    - Stocks
      - AEX index Stocks
      - AEX ESG Stocks
    - Indices
    - Funds
    - Bonds
    - ETFs
    - Structured products
  - Derivative products
  - Company regulated news
    - Latest
    - Archive
- Brussels
  - Cash products
  - Derivative products
  - Company regulated news
    - Latest
    - Archive
  - Expert Market
- Dublin
- Lisbon
  - Cash Products
  - Derivative products
  - Company regulated news
    - Latest
    - Archive
- Milan
  - Cash Products
  - Derivative products
  - IPOs
- Oslo
  - Cash Products
  - Derivatives
    - Derivative products
    - Quote Vendor Codes
  - Company regulated news
    - Latest
    - Archive
  - Financial calendars
  - Primary insiders
- Paris
  - Cash Products
  - Derivative products
  - Company regulated news
    - Latest
    - Archive
Equities
- All Markets directories
- Company regulated news
  - Latest
  - Archive
- IPOs
  - All IPOs
- Listing sponsors
- Euronext Tech Leaders
- Family business
Indices
ETFs
- Directory
- ESG ETFs
Funds
Fixed Income
- ESG Bonds
- 1.5° Bonds
- All Markets directories
  - All Markets
  - Amsterdam
  - Brussels
  - Dublin
  - Lisbon
  - Oslo
  - Milan
  - Paris
Structured Products
Equity Derivatives
Commodities
Education
Resources